IVDT_In Vitro Diagnostics Technology

IVD Technology, Fall 2013

Issue link: http://dc.cn.ubm-us.com/i/182700

Contents of this Issue

Navigation

Page 24 of 35

Approximately 750,000 Brazilians live with HIV/AIDS. Brazil started ofering free antiretroviral drugs to anyone infected with HIV in 1996. Te program is now seen as very successful and a possible model for other countries. Brazil's 1988 constitution declared healthcare to be a civil right and its provision the duty of the state. Historically, the country has been saddled with inadequate public health services owing to insufcient funding and limitations on what is covered, but government fnances are in good condition now and funding is being made available to improve public services. Despite the constitution, around 60% of Brazil's spending on healthcare is privately funded. Public spending accounts for just 3.1% of GDP, while private spending represents an additional 4.4%. We estimate that 25% of Brazilians have private medical insurance and get coverage from Brazil's private medi- cal sector. Brazilians often get medical insurance in the form of a contract between their employers and private health insurers. Te diagnostics market is divided between 60 and 65% in the public sector and 35 to 40% in the private sector. Tere are signifcant variations by market segment. For example allergy, cancer and hormones are predominantly a private market, while the public sector is stronger in fow cytometry. Laboratories We estimate the total number of labs in Brazil at 12,000, but this includes approximately 6000 that are little more than collection sites. Te number of laboratories that represent potential customers is closer to 6000. Laboratory consolidation has been a fact of the Brazilian IVD market for all of the 18 years we have been reporting on the country. In 2007, we wrote that Brazil had about 10 large private laboratories (or chains of labs). In 2010, we wrote that there were around fve large private labs that had bought up most of the midsized laboratories and were now buying small labs and generally turning them into collection sites. We now think the number of large labs is four. Typically focused on their own region, these labs are now opening branches in each other's territories as several seek to become truly national chains. Te largest private laboratory in the country, and the fourth largest in the world, is Diagnosticos da America (DASA; www.diagnosticosdaamerica. com.br). DASA was created in 1999 by combining Delboni and Lavoisier of São Paulo with Brownstein and Lamina of Rio de Janeiro. It later bought Frischmann-Aisengart in Curitiba. DASA currently operates around 300 laboratories under 20 or so diferent brand names and is active in 13 states. From a supplier perspective, DASA is thought of as a high-volume, low-proft customer. Hermes Pardini SPHERO TM SPHEROTM Fluorescent Microparticles Brilliant Particles, Infinite Possibilities Polystyrene Fluorescent Microspheres Applications include bioimaging and biosensing Monodisperse with stable fluorescence Functionalized Fluorescent Microspheres For covalent coupling to proteins or ligands Used as fluorescent tracers for cell surface markers after coating Coated Fluorescent Microspheres Available with Streptavidin, Avidin, Biotin, Protein A, Protein G, Goat anti-Mouse IgG, or other proteins of interest Used in agglutination and lateral flow assays Spherotech Visit us at COPAMED 2013, Hall 08a Stand H04 27845 Irma Lee Circle, Unit 101 Lake Forest, IL 60045 Tel (847) 680-8922 Fax (847) 680-8927 www.spherotech.com I VD T EC H N O LO G Y | FALL 2 0 1 3 2 5 magenta cyan yellow black ES323645_IV1309_025.pgs 09.24.2013 02:24 UBM

Articles in this issue

Links on this page

Archives of this issue

view archives of IVDT_In Vitro Diagnostics Technology - IVD Technology, Fall 2013